Inhaled Nanomedicines Using a Vibrating-mesh Nebuliser: Particle Size Considerations

Abstract

Vibrating-mesh nebulisers have a reputation for having a gentle and successful aerosolization process while preserving the integrity of biologic formulations. The main component of a vibrating-mesh nebuliser is the oscillating membrane. This is formed by thousands of micron-sized pores that oscillate to generate a fine mist. These pores have the potential to be blocked depending on the formulation, especially if it is not a homogeneous solution. In this experiment, poly-lactic-co-glycolic acid nanoparticles (PLGA-NPs) of three varied sizes (100, 200 and 500 nm) were nebulised. The aim was to understand the impact of particle size and concentration on nebulisation using the FOX® vibrating-mesh nebuliser. PLGA-NPs of 100 and 200 nm size were successfully nebulised over a wide concentration range (from 0.1 to 10 mg/ml) in terms of percentage aerosolised and nebulisation time. Particles of larger size (500 nm) showed a long nebulisation time which might correlate with membrane blockages. A substantial proportion of the nanomedicines in the market and under development have a particle size around 100-200 nm. The result of this study showed that the FOX® vibrating-mesh nebuliser can be a suitable platform to successfully deliver these types of nanomedicines to the lungs. 

Keywords

Nanomedicines, Mesh nebuliser, lung therapy, particle size

How to Cite

Puig, M., Keegan, G. & Munro, S., (2023) “Inhaled Nanomedicines Using a Vibrating-mesh Nebuliser: Particle Size Considerations”, British Journal of Pharmacy 8(2). doi: https://doi.org/10.5920/bjpharm.1369

85

Views

23

Downloads

Share

Authors

Mireia Puig (Vectura Limited)
Gemma Keegan
Sandy Munro

Download

Issue

Dates

Licence

Creative Commons Attribution 4.0

Identifiers

Peer Review

This article has been peer reviewed.

File Checksums (MD5)

  • Fulltext: 58c133e0321f226817694c4de29c085f